RxDoctor Payments Data

Jose Hernan Posas, MD

Neurology · Charlottesville, VANPI 1548402399

Payments from drug & device makers

$8,683in general payments, 2019–2025

Across 55 payments — averaging $157.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • AbbVie$962
  • Nevro Corp.$108
  • Lilly USA, LLC$99
  • AstraZeneca$91
  • Greenwich Biosciences, Inc.$83
  • plus $141 from 5 others

What the payments were for

  • Consulting fees$7,41385%
  • Food & beverage$1,27115%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$7,200
AbbVie(2 entities)39$962
Nevro Corp.1$108
Lilly USA, LLC1$99
AstraZeneca2$91
Greenwich Biosciences, Inc.1$83
Amgen4$71
Biohaven Pharmaceutical Holding Company Ltd.1$22
Novartis1$20
UCB, Inc.1$15
Zyla Life Sciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,683 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$12,414
Medicare patients
81
Services billed
137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$109,538
Nurtec OdtRimegepant Sulfate50$83,078
Aimovig AutoinjectorErenumab-Aooe50$36,368
UbrelvyUbrogepant37$36,226
Emgality PenGalcanezumab-Gnlm31$21,141
QuliptaAtogepant16$16,404
Gabapentin55$1,410
RizatriptanRizatriptan Benzoate35$463
Baclofen36$442
Topiramate49$302
Venlafaxine Hcl ErVenlafaxine Hcl20$263
Ondansetron OdtOndansetron16$241
Sumatriptan Succinate26$178
Diclofenac Sodium15$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$7,200$83,07850 claims
AbbVieUbrelvy, Qulipta$962$52,63053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 neurology providers in Virginia.

Other neurology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →